JP2021524472A5 - - Google Patents
Info
- Publication number
- JP2021524472A5 JP2021524472A5 JP2020565417A JP2020565417A JP2021524472A5 JP 2021524472 A5 JP2021524472 A5 JP 2021524472A5 JP 2020565417 A JP2020565417 A JP 2020565417A JP 2020565417 A JP2020565417 A JP 2020565417A JP 2021524472 A5 JP2021524472 A5 JP 2021524472A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- treatment
- therapeutic effect
- patient
- Prior art date
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024021644A JP7751362B2 (ja) | 2018-05-24 | 2024-02-16 | 乾癬性関節炎の治療方法 |
| JP2025157844A JP2025183397A (ja) | 2018-05-24 | 2025-09-24 | 乾癬性関節炎の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1808575.3A GB201808575D0 (en) | 2018-05-24 | 2018-05-24 | Methods for the treatment of psoriatic arthrits |
| GB1808575.3 | 2018-05-24 | ||
| PCT/EP2019/063283 WO2019224283A1 (en) | 2018-05-24 | 2019-05-23 | Methods for the treatment of psoriatic arthritis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024021644A Division JP7751362B2 (ja) | 2018-05-24 | 2024-02-16 | 乾癬性関節炎の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021524472A JP2021524472A (ja) | 2021-09-13 |
| JP2021524472A5 true JP2021524472A5 (https=) | 2022-05-31 |
| JPWO2019224283A5 JPWO2019224283A5 (https=) | 2022-05-31 |
Family
ID=62812304
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565417A Pending JP2021524472A (ja) | 2018-05-24 | 2019-05-23 | 乾癬性関節炎の治療方法 |
| JP2024021644A Active JP7751362B2 (ja) | 2018-05-24 | 2024-02-16 | 乾癬性関節炎の治療方法 |
| JP2025157844A Pending JP2025183397A (ja) | 2018-05-24 | 2025-09-24 | 乾癬性関節炎の治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024021644A Active JP7751362B2 (ja) | 2018-05-24 | 2024-02-16 | 乾癬性関節炎の治療方法 |
| JP2025157844A Pending JP2025183397A (ja) | 2018-05-24 | 2025-09-24 | 乾癬性関節炎の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12329758B2 (https=) |
| EP (1) | EP3801548A1 (https=) |
| JP (3) | JP2021524472A (https=) |
| CN (1) | CN112203660B (https=) |
| AU (2) | AU2019273664B2 (https=) |
| CA (1) | CA3101386A1 (https=) |
| GB (1) | GB201808575D0 (https=) |
| MA (1) | MA52738A (https=) |
| WO (1) | WO2019224283A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| EP4178616A4 (en) * | 2020-07-13 | 2024-07-24 | Janssen Biotech, Inc. | SAFE AND EFFECTIVE METHOD FOR TREATING PSORIATIC ARTHRITIS USING A SPECIFIC ANTI-IL23 ANTIBODY |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000044722A1 (en) | 1999-01-29 | 2000-08-03 | Chugai Seiyaku Kabushiki Kaisha | Chondrongenesis promotors and indolin-2-one derivatives |
| US20040138285A1 (en) | 2001-04-27 | 2004-07-15 | Makoto Okazaki | Chondrogenesis promoters |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| JPWO2004039816A1 (ja) | 2002-10-29 | 2006-03-02 | 塩野義製薬株式会社 | セフェム化合物の無機酸塩の結晶 |
| CA2515190A1 (en) | 2003-02-14 | 2004-08-26 | Pfizer Products Inc. | Triazolo-pyridines as anti-inflammatory compounds |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| US20070004658A1 (en) | 2004-06-21 | 2007-01-04 | Nick Vandeghinste | Method and means for treatment of osteoarthritis |
| EP1786811A2 (en) | 2004-08-18 | 2007-05-23 | Pharmacia & Upjohn Company LLC | Triazolopyridine compounds |
| WO2006038116A2 (en) | 2004-10-07 | 2006-04-13 | Warner-Lambert Company Llc | Triazolopyridine derivatives as antibacterial agents |
| GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| JP5336375B2 (ja) | 2006-08-30 | 2013-11-06 | セルゾーム リミテッド | キナーゼ阻害剤としてのトリアゾール誘導体 |
| CL2008001626A1 (es) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
| US8053574B2 (en) | 2007-07-18 | 2011-11-08 | Novartis Ag | Organic compounds |
| WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| CA2691448A1 (en) | 2007-08-31 | 2009-03-05 | Dominique Swinnen | Triazolopyridine compounds and their use as ask inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| BRPI0909945A2 (pt) | 2008-06-20 | 2015-07-28 | Genentech Inc | "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase" |
| WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| WO2010010186A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| WO2010013768A1 (ja) | 2008-07-31 | 2010-02-04 | 第一三共株式会社 | チアゾリジンジオン化合物の結晶及びその製造方法 |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| JP2013049632A (ja) | 2011-08-30 | 2013-03-14 | Kowa Co | ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤 |
| SA112330992B1 (ar) | 2011-11-10 | 2015-09-13 | كيورين فارماسوتيكال كو.، ليمتد | صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي |
| US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| AU2013279597B2 (en) | 2012-06-22 | 2017-04-20 | Alfasigma S.P.A. | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| CA2982630A1 (en) * | 2015-04-13 | 2016-10-20 | Galapagos Nv | Methods for the treatment of inflammatory disorders |
| RS64677B1 (sr) | 2015-04-13 | 2023-11-30 | Galapagos Nv | Metode lečenja kardiovaskularnih poremećaja |
| US20170173034A1 (en) * | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| PL3595667T3 (pl) * | 2017-03-14 | 2024-03-18 | Galapagos Nv | Kompozycje farmaceutyczne zawierające inhibitor jak |
-
2018
- 2018-05-24 GB GBGB1808575.3A patent/GB201808575D0/en not_active Ceased
-
2019
- 2019-05-23 AU AU2019273664A patent/AU2019273664B2/en active Active
- 2019-05-23 US US17/057,946 patent/US12329758B2/en active Active
- 2019-05-23 CN CN201980034599.1A patent/CN112203660B/zh active Active
- 2019-05-23 EP EP19726950.9A patent/EP3801548A1/en active Pending
- 2019-05-23 WO PCT/EP2019/063283 patent/WO2019224283A1/en not_active Ceased
- 2019-05-23 MA MA052738A patent/MA52738A/fr unknown
- 2019-05-23 JP JP2020565417A patent/JP2021524472A/ja active Pending
- 2019-05-23 CA CA3101386A patent/CA3101386A1/en active Pending
-
2024
- 2024-02-16 JP JP2024021644A patent/JP7751362B2/ja active Active
-
2025
- 2025-04-22 AU AU2025202777A patent/AU2025202777A1/en active Pending
- 2025-05-13 US US19/206,213 patent/US20260108530A1/en active Pending
- 2025-09-24 JP JP2025157844A patent/JP2025183397A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250066466A1 (en) | Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists | |
| Chirappapha et al. | Idiopathic granulomatous mastitis: A retrospective cohort study between 44 patients with different treatment modalities | |
| JP2023537403A (ja) | 痛風を治療する方法 | |
| JP2021524472A5 (https=) | ||
| JP2025183397A (ja) | 乾癬性関節炎の治療方法 | |
| US20220363749A1 (en) | Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists | |
| Kant et al. | Intravenous ferric carboxymaltose rapidly increases haemoglobin and serum ferritin among pregnant females with moderate-to-severe anaemia: A single-arm, open-label trial. | |
| TW202405014A (zh) | 藉由投予ｉｌ－６ｒ拮抗劑治療風濕性多肌痛症的組成物及方法 | |
| US20240368294A1 (en) | Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis | |
| Duquenne et al. | Glucocorticoid-sparing effect of first-year anti-TNFα treatment in rheumatoid arthritis (CORPUS Cohort) | |
| TW202517276A (zh) | 用於治療自體免疫及發炎疾病之rip1激酶抑制劑之調配物及劑量療法 | |
| JPWO2019224283A5 (https=) | ||
| US20240301058A1 (en) | Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease | |
| RU2860237C2 (ru) | Способы лечения подагры | |
| Branch et al. | Expert consensus on tuberculosis preventive treatment for individuals at high risk of developing active diseases from latent tuberculosis infection in comprehensive medical facilities | |
| Liao et al. | 557. Trends in Remdesivir Treatment Over the Course of the COVID-19 Pandemic | |
| Ranasinghe et al. | RevMED: 300 SBAs in Medicine and Surgery | |
| AU2024332373A1 (en) | Methods of using factor b inhibitors | |
| Doffman et al. | AZD8630/AMG 104, an inhaled Anti-TSLP antibody fragment, for moderate-to-severe asthma: a phase 1 randomized controlled trial | |
| WO2025027388A1 (en) | Obefazimod for treatment of ulcerative colitis | |
| Ramirez et al. | 337. MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A SINGLE CENTRE REAL-LIFE EXPERIENCE | |
| Bird et al. | Clinical Study AC-CUTE: An Open-Label Study to Evaluate Progression of Structural Joint Damage and Inflammation in Subjects with Moderate to Severe Rheumatoid Arthritis | |
| JP2026513190A (ja) | シェーグレン症候群の治療及び予防のためのＣＤ４０Ｌ特異的Ｔｎ３由来足場 | |
| Mehta et al. | Clinical Medicine for the MRCP PACES: Volume 2: History-Taking, Communication and Ethics | |
| CN118076369A (zh) | Cd40l特异性tn3衍生支架及其用于治疗和预防类风湿性关节炎的方法 |